Advice
Recommended for restricted use within NHS Scotland
REASONS FOR ADVICE
Moxifloxacin (Avelox), a new fluoroquinolone antibiotic, for the treatment of acute exacerbations of chronic bronchitis, should be restricted to patients who fail to respond to conventional therapy or in whom this is contra-indicated. Its use should be in accordance with British Thoracic Society (BTS) and Scottish Intercollegiate Guidelines Network (SIGN) guidance.
Download detailed advice22KB (PDF)
Medicine details
- Medicine name:
- Moxifloxacin (Avelox®)
- SMC ID:
- 70/03
- Indication:
- Acute exacerbations of chronic bronchitis
- Pharmaceutical company
- Bayer plc/Bayer Schering Pharma
- BNF chapter
- Infections
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 13 October 2003